Allianz Asset Management’s Ascendis Pharma A/S ASND Stock Holding History

Allianz Asset Management’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.09M	Sell	4,100 -1,200	-23%	-$280K	﹤0.01%	1876
2026 Q1	$1.21M	Sell	5,300 -648	-11%	-$145K	﹤0.01%	1684
2025 Q4	$1.27M	Sell	5,948 -2,376	-29%	-$491K	﹤0.01%	1656
2025 Q3	$1.65M	Sell	8,324 -976	-10%	-$182K	﹤0.01%	1566
2025 Q2	$1.61M	Buy	9,300 +5,500	+145%	+$896K	﹤0.01%	1543
2025 Q1	$592K	Sell	3,800 -175	-4%	-$25K	﹤0.01%	1825
2024 Q4	$547K	Buy	3,975 +8	+0.2%	+$1.05K	﹤0.01%	1837
2024 Q3	$592K	Buy	3,967 +200	+5%	+$27K	﹤0.01%	1811
2024 Q2	$514K	Buy	3,767 +4	+0.1%	+$544	﹤0.01%	1825
2024 Q1	$569K	Buy	3,763 +163	+5%	+$23.3K	﹤0.01%	1580
2023 Q4	$453K	Buy	+3,600	New	+$359K	﹤0.01%	1882
2023 Q2	–	Sell	-11,200	Closed	-$1.2M	–	2152
2023 Q1	$1.2M	Buy	+11,200	New	+$1.28M	﹤0.01%	1616
2022 Q3	–	Sell	-18,105	Closed	-$1.68M	–	1891
2022 Q2	$1.68M	Hold	18,105	–	–	﹤0.01%	1483
2022 Q1	$2.13M	Sell	18,105 -34,910	-66%	-$4.04M	﹤0.01%	1573
2021 Q4	$7.15M	Buy	53,015 +9,355	+21%	+$1.39M	﹤0.01%	1109
2021 Q3	$6.96M	Buy	43,660 +26,765	+158%	+$3.66M	0.01%	1151
2021 Q2	$2.22M	Sell	16,895 -15,330	-48%	-$2.04M	﹤0.01%	1430
2021 Q1	$4.15M	Sell	32,225 -2,245	-7%	-$341K	﹤0.01%	1142
2020 Q4	$5.75M	Hold	34,470	–	–	0.01%	1000
2020 Q3	$5.32M	Sell	34,470 -4,270	-11%	-$614K	0.01%	963
2020 Q2	$5.73M	Buy	38,740 +1,645	+4%	+$226K	0.01%	1148
2020 Q1	$4.18M	Sell	37,095 -1,385	-4%	-$180K	0.01%	1230
2019 Q4	$5.35M	Sell	38,480 -2,825	-7%	-$314K	﹤0.01%	1455
2019 Q3	$3.98M	Sell	41,305 -13,055	-24%	-$1.46M	﹤0.01%	1554
2019 Q2	$6.26M	Sell	54,360 -3,070	-5%	-$367K	0.01%	1395
2019 Q1	$6.76M	Buy	57,430 +13,610	+31%	+$1.19M	0.01%	1313
2018 Q4	$2.69M	Sell	43,820 -34,300	-44%	-$2.16M	﹤0.01%	1647
2018 Q3	$5.54M	Sell	78,120 -69,340	-47%	-$4.77M	0.01%	1516
2018 Q2	$9.81M	Sell	147,460 -31,260	-17%	-$2.06M	0.01%	1258
2018 Q1	$11.7M	Buy	178,720 +350	+0.2%	+$19.7K	0.01%	1175
2017 Q4	$7.14M	Buy	178,370 +57,920	+48%	+$2.11M	0.01%	1481
2017 Q3	$4.37M	Buy	+120,450	New	+$3.46M	﹤0.01%	1682

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Allianz Asset Management's ASND Position: Q2 2026 in Review

Allianz Asset Management reduced its Ascendis Pharma A/S (ASND) stake by 23% in Q2 2026, selling an estimated $280K and leaving 4,100 shares worth $1.09M. The position accounts for ﹤0.01% of the portfolio, ranked #1876.

Allianz Asset Management first reported a position in ASND in Q3 2017 and has held it in 32 quarters since. The position peaked at $11.7M in Q1 2018. 312 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

Allianz Asset Management held 4,100 shares of Ascendis Pharma A/S worth $1.09M as of Q2 2026.
Allianz Asset Management sold 1,200 Ascendis Pharma A/S shares in Q2 2026, an estimated $280K.
Ascendis Pharma A/S made up ﹤0.01% of Allianz Asset Management's portfolio in Q2 2026, its #1876 holding.
Allianz Asset Management first reported a position in Ascendis Pharma A/S in Q3 2017 and has held it in 32 quarters since.
Allianz Asset Management's Ascendis Pharma A/S position peaked at $11.7M in Q1 2018.
312 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on Allianz Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.